Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice

Tomoko Iwata, Cui Ling Li, Chu Xia Deng, Clair Ann Francomano

Research output: Contribution to journalArticle

Abstract

Several gain-of-function mutations in a receptor tyrosine kinase, fibroblast growth factor receptor 3 (FGFR3), cause dwarfism in humans. Two particularly severe dwarfisms, thanatophoric dysplasia type II (TDII) and severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), are associated with glutamic acid (E) and methionine (M) substitutions at the K650 residue in the kinase domain. TDII is lethal at birth, whereas most of the SADDAN patients survive the perinatal period. However, FGFR3 with the SADDAN mutation is more activated than FGFR3 with the TDII mutation in vitro. To find out whether the K650M mutation also causes the SADDAN phenotype, we introduced the corresponding point mutation (K644M) into the mouse Fgfr3 gene. Heterozygous mutant mice show a phenotype similar to human SADDAN, e.g. the majority of the SADDAN mice survive the perinatal period. This suggests that the survival of SADDAN patients is indeed attributed to the K650M mutation in FGFR3. The long bone abnormalities in SADDAN mice are milder than the TDII model. In addition, overgrowth of the cartilaginous tissues is observed in the rib cartilage, trachea and nasal septum. The FGF ligand at the low concentration differentially activates Map kinase in primary chondrocyte cultures from wildtype and SADDAN mice. Comparisons of the molecular bases of the phenotypic differences in SADDAN and TDII mice may increase our understanding of the factors that influence the severity in these two related skeletal dysplasias.

Original languageEnglish (US)
Pages (from-to)1255-1264
Number of pages10
JournalHuman Molecular Genetics
Volume10
Issue number12
StatePublished - Jun 1 2001

Fingerprint

Achondroplasia
Thanatophoric Dysplasia
Mutation
Receptor, Fibroblast Growth Factor, Type 3
Survival
Phosphotransferases
Phenotype
Nasal Septum
Dwarfism
Receptor Protein-Tyrosine Kinases
Ribs
Chondrocytes
Trachea
Point Mutation
Methionine
Cartilage
Glutamic Acid
Parturition

ASJC Scopus subject areas

  • Genetics

Cite this

Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice. / Iwata, Tomoko; Li, Cui Ling; Deng, Chu Xia; Francomano, Clair Ann.

In: Human Molecular Genetics, Vol. 10, No. 12, 01.06.2001, p. 1255-1264.

Research output: Contribution to journalArticle

Iwata, Tomoko ; Li, Cui Ling ; Deng, Chu Xia ; Francomano, Clair Ann. / Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice. In: Human Molecular Genetics. 2001 ; Vol. 10, No. 12. pp. 1255-1264.
@article{06eff0d0824b4d84ab528c0e6aaf5cb7,
title = "Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice",
abstract = "Several gain-of-function mutations in a receptor tyrosine kinase, fibroblast growth factor receptor 3 (FGFR3), cause dwarfism in humans. Two particularly severe dwarfisms, thanatophoric dysplasia type II (TDII) and severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), are associated with glutamic acid (E) and methionine (M) substitutions at the K650 residue in the kinase domain. TDII is lethal at birth, whereas most of the SADDAN patients survive the perinatal period. However, FGFR3 with the SADDAN mutation is more activated than FGFR3 with the TDII mutation in vitro. To find out whether the K650M mutation also causes the SADDAN phenotype, we introduced the corresponding point mutation (K644M) into the mouse Fgfr3 gene. Heterozygous mutant mice show a phenotype similar to human SADDAN, e.g. the majority of the SADDAN mice survive the perinatal period. This suggests that the survival of SADDAN patients is indeed attributed to the K650M mutation in FGFR3. The long bone abnormalities in SADDAN mice are milder than the TDII model. In addition, overgrowth of the cartilaginous tissues is observed in the rib cartilage, trachea and nasal septum. The FGF ligand at the low concentration differentially activates Map kinase in primary chondrocyte cultures from wildtype and SADDAN mice. Comparisons of the molecular bases of the phenotypic differences in SADDAN and TDII mice may increase our understanding of the factors that influence the severity in these two related skeletal dysplasias.",
author = "Tomoko Iwata and Li, {Cui Ling} and Deng, {Chu Xia} and Francomano, {Clair Ann}",
year = "2001",
month = "6",
day = "1",
language = "English (US)",
volume = "10",
pages = "1255--1264",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Highly activated Fgfr3 with the K644M mutation causes prolonged survival in severe dwarf mice

AU - Iwata, Tomoko

AU - Li, Cui Ling

AU - Deng, Chu Xia

AU - Francomano, Clair Ann

PY - 2001/6/1

Y1 - 2001/6/1

N2 - Several gain-of-function mutations in a receptor tyrosine kinase, fibroblast growth factor receptor 3 (FGFR3), cause dwarfism in humans. Two particularly severe dwarfisms, thanatophoric dysplasia type II (TDII) and severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), are associated with glutamic acid (E) and methionine (M) substitutions at the K650 residue in the kinase domain. TDII is lethal at birth, whereas most of the SADDAN patients survive the perinatal period. However, FGFR3 with the SADDAN mutation is more activated than FGFR3 with the TDII mutation in vitro. To find out whether the K650M mutation also causes the SADDAN phenotype, we introduced the corresponding point mutation (K644M) into the mouse Fgfr3 gene. Heterozygous mutant mice show a phenotype similar to human SADDAN, e.g. the majority of the SADDAN mice survive the perinatal period. This suggests that the survival of SADDAN patients is indeed attributed to the K650M mutation in FGFR3. The long bone abnormalities in SADDAN mice are milder than the TDII model. In addition, overgrowth of the cartilaginous tissues is observed in the rib cartilage, trachea and nasal septum. The FGF ligand at the low concentration differentially activates Map kinase in primary chondrocyte cultures from wildtype and SADDAN mice. Comparisons of the molecular bases of the phenotypic differences in SADDAN and TDII mice may increase our understanding of the factors that influence the severity in these two related skeletal dysplasias.

AB - Several gain-of-function mutations in a receptor tyrosine kinase, fibroblast growth factor receptor 3 (FGFR3), cause dwarfism in humans. Two particularly severe dwarfisms, thanatophoric dysplasia type II (TDII) and severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), are associated with glutamic acid (E) and methionine (M) substitutions at the K650 residue in the kinase domain. TDII is lethal at birth, whereas most of the SADDAN patients survive the perinatal period. However, FGFR3 with the SADDAN mutation is more activated than FGFR3 with the TDII mutation in vitro. To find out whether the K650M mutation also causes the SADDAN phenotype, we introduced the corresponding point mutation (K644M) into the mouse Fgfr3 gene. Heterozygous mutant mice show a phenotype similar to human SADDAN, e.g. the majority of the SADDAN mice survive the perinatal period. This suggests that the survival of SADDAN patients is indeed attributed to the K650M mutation in FGFR3. The long bone abnormalities in SADDAN mice are milder than the TDII model. In addition, overgrowth of the cartilaginous tissues is observed in the rib cartilage, trachea and nasal septum. The FGF ligand at the low concentration differentially activates Map kinase in primary chondrocyte cultures from wildtype and SADDAN mice. Comparisons of the molecular bases of the phenotypic differences in SADDAN and TDII mice may increase our understanding of the factors that influence the severity in these two related skeletal dysplasias.

UR - http://www.scopus.com/inward/record.url?scp=0035363725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035363725&partnerID=8YFLogxK

M3 - Article

C2 - 11406607

AN - SCOPUS:0035363725

VL - 10

SP - 1255

EP - 1264

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 12

ER -